GeneSoft Factive for mild to moderate CAP
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's Anti-Infective Drugs Advisory Committee recommends approval of GeneSoft's Factive (gemifloxacin) for community-acquired pneumonia (18-0, one abstention) and acute bacterial exacerbation of chronic bronchitis (15-3, one abstention) during March 4 review. Committee members suggested limiting the CAP indication for the quinolone antibiotic to mild to moderate pneumonia due to multi-drug resistant strains for a seven-day treatment period. FDA raised safety concerns about rash, QT prolongation and hepatotoxicity. Study data showed rash rates in women under 40 to be 31.7% for Factive versus 4.3% for ciprofloxacin. The committee said the incidence of rash should be included in labelin
You may also be interested in...
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.